HC Wainwright Analysts Raise Earnings Estimates for OLMA

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Investment analysts at HC Wainwright raised their Q1 2026 EPS estimates for Olema Pharmaceuticals in a report issued on Monday, March 16th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.50) per share for the quarter, up from their previous forecast of ($0.51). HC Wainwright has a “Buy” rating and a $38.00 price target on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.58) EPS, Q4 2026 earnings at ($0.61) EPS, FY2026 earnings at ($2.23) EPS, FY2027 earnings at ($2.29) EPS, FY2028 earnings at ($1.87) EPS, FY2029 earnings at ($1.39) EPS and FY2030 earnings at ($0.64) EPS.

OLMA has been the subject of a number of other reports. Guggenheim decreased their price target on shares of Olema Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday. TD Cowen reaffirmed a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Thursday, January 22nd. Piper Sandler began coverage on Olema Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 target price for the company. Finally, The Goldman Sachs Group lowered their target price on Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating for the company in a research note on Wednesday. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Olema Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $44.89.

Olema Pharmaceuticals Trading Down 3.1%

Shares of OLMA opened at $14.60 on Wednesday. Olema Pharmaceuticals has a 1-year low of $2.86 and a 1-year high of $36.26. The company has a current ratio of 9.95, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average price is $23.56 and its 200-day moving average price is $18.70. The firm has a market capitalization of $1.00 billion, a price-to-earnings ratio of -7.85 and a beta of 1.92.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.01.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, insider Shawnte Mitchell sold 25,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total transaction of $606,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Naseem Zojwalla sold 99,509 shares of Olema Pharmaceuticals stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $27.66, for a total transaction of $2,752,418.94. Following the transaction, the insider owned 4,488 shares of the company’s stock, valued at $124,138.08. The trade was a 95.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 805,501 shares of company stock valued at $23,003,832 over the last three months. 16.36% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bain Capital Life Sciences Investors LLC boosted its holdings in Olema Pharmaceuticals by 24.3% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock worth $212,716,000 after acquiring an additional 1,664,687 shares in the last quarter. Paradigm Biocapital Advisors LP grew its stake in shares of Olema Pharmaceuticals by 11.0% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,544,172 shares of the company’s stock worth $188,604,000 after acquiring an additional 750,000 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Olema Pharmaceuticals by 87.1% during the fourth quarter. Janus Henderson Group PLC now owns 6,710,194 shares of the company’s stock valued at $167,901,000 after acquiring an additional 3,124,345 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Olema Pharmaceuticals by 11.4% during the fourth quarter. Vanguard Group Inc. now owns 3,561,355 shares of the company’s stock valued at $89,034,000 after acquiring an additional 364,035 shares in the last quarter. Finally, Deep Track Capital LP raised its position in shares of Olema Pharmaceuticals by 0.8% in the 3rd quarter. Deep Track Capital LP now owns 3,470,172 shares of the company’s stock worth $33,973,000 after purchasing an additional 27,339 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Key Olema Pharmaceuticals News

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Major price‑target upgrades from big banks: Citigroup raised its target to $62 (buy) and JPMorgan bumped its target to $58 (overweight), signaling outsized upside relative to the current share level and supporting buy‑side interest. Benzinga
• Positive Sentiment: HC Wainwright lifted earnings estimates across multiple quarters and extended horizon upgrades (FY2026–FY2030) while keeping a Buy rating and $38 target — this reduces near‑term downside in forecasts and is a supportive fundamental datapoint. MarketBeat
• Positive Sentiment: Recent operational/clinical and earnings headlines have attracted capital: a report notes a $68.7M investor bet tied to a breast cancer drug aimed at a 2027 launch, and coverage noting the stock rallied after better‑than‑expected earnings — both draw attention from momentum and event‑driven investors. Globe and Mail American Banking News
• Neutral Sentiment: Presentation of preclinical data at AACR (palazestrant & OP‑3136) is a nearer‑term scientific catalyst; positive data would be bullish, but upcoming abstracts/presentations are binary and uncertain. Business Insider
• Neutral Sentiment: Technicals show a steep recent pullback (down ~33% in 4 weeks) and the stock is in oversold territory—this could set up a short‑term reversal if selling eases, but it also reflects volatility after the prior run. Zacks
• Neutral Sentiment: Guggenheim trimmed its target slightly (to $38) but maintained a Buy — a modest downgrade of enthusiasm rather than a reversal. Benzinga
• Negative Sentiment: Goldman Sachs cut its target from $38 to $27 (still a Buy), which reduces consensus upside and may weigh on sentiment for more cautious investors; mixed analyst signals increase short‑term volatility. Benzinga

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.